MX2022012506A - Métodos y medios para modificar la hemodinámica en infecciones. - Google Patents

Métodos y medios para modificar la hemodinámica en infecciones.

Info

Publication number
MX2022012506A
MX2022012506A MX2022012506A MX2022012506A MX2022012506A MX 2022012506 A MX2022012506 A MX 2022012506A MX 2022012506 A MX2022012506 A MX 2022012506A MX 2022012506 A MX2022012506 A MX 2022012506A MX 2022012506 A MX2022012506 A MX 2022012506A
Authority
MX
Mexico
Prior art keywords
infection
hemodynamics
infections
modify
methods
Prior art date
Application number
MX2022012506A
Other languages
English (en)
Spanish (es)
Inventor
Gert Wensvoort
Eric Claassen
Johan Renes
Original Assignee
Biotempt Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotempt Bv filed Critical Biotempt Bv
Publication of MX2022012506A publication Critical patent/MX2022012506A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2022012506A 2020-04-06 2021-04-06 Métodos y medios para modificar la hemodinámica en infecciones. MX2022012506A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063005999P 2020-04-06 2020-04-06
US202063045737P 2020-06-29 2020-06-29
US202063085771P 2020-09-30 2020-09-30
PCT/NL2021/050223 WO2021206547A1 (en) 2020-04-06 2021-04-06 Methods and means for modifying hemodynamics in infections

Publications (1)

Publication Number Publication Date
MX2022012506A true MX2022012506A (es) 2023-01-16

Family

ID=75581581

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012506A MX2022012506A (es) 2020-04-06 2021-04-06 Métodos y medios para modificar la hemodinámica en infecciones.

Country Status (9)

Country Link
US (1) US20230241155A1 (https=)
EP (1) EP4132556A1 (https=)
JP (2) JP2023521744A (https=)
KR (1) KR20230003495A (https=)
AU (1) AU2021252821A1 (https=)
CA (1) CA3174852A1 (https=)
CO (1) CO2022015018A2 (https=)
MX (1) MX2022012506A (https=)
WO (1) WO2021206547A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4021481A1 (en) * 2019-08-30 2022-07-06 Biotempt B.V. Q-er peptide
AU2021354766A1 (en) * 2020-09-30 2023-05-11 Biotempt B.V. Autophagy-inhibiting peptide and organic acid salt thereof addressing issues of vascular permeability
WO2025191033A1 (en) 2024-03-13 2025-09-18 Biotempt B.V. Per-operative treatment of post-operative complications (poc)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ542791A (en) * 2003-04-08 2008-04-30 Biotempt Bv Compositions for mucosal and oral administration comprising HCG fragments
EP4021481A1 (en) * 2019-08-30 2022-07-06 Biotempt B.V. Q-er peptide
CA3152346A1 (en) * 2019-09-30 2021-04-08 Roelof Peter Pickkers Methods of treatment for modifying hemodynamics

Also Published As

Publication number Publication date
JP2026027378A (ja) 2026-02-18
EP4132556A1 (en) 2023-02-15
WO2021206547A1 (en) 2021-10-14
KR20230003495A (ko) 2023-01-06
JP2023521744A (ja) 2023-05-25
CA3174852A1 (en) 2021-10-14
US20230241155A1 (en) 2023-08-03
CO2022015018A2 (es) 2022-10-31
AU2021252821A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
CO2022015018A2 (es) Métodos y medios para modificar la hemodinámica en infecciones
CO2024006742A2 (es) Compuestos terapéuticos para la infección por el virus del vih
DOP2023000187A (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso
MX2022011671A (es) Vacunas contra el coronavirus y metodos de uso.
MX2023013738A (es) Analogos de la camptotecina, conjugados y metodos de uso.
AR121361A1 (es) Vacuna
MX2020009602A (es) Formulaciones de pulverizacion de epinefrina.
MX388408B (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv
CL2021002582A1 (es) Vacunas contra el circovirus porcino tipo 3 (pcv3), su producción y usos
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
JP1732835S (ja) ネットタイプアトマイザー
MX2022014034A (es) Métodos para tratar covid-19 con el uso de bardoxolona metilo o análogos de esta.
CO2024012622A2 (es) Anticuerpos capaces de unirse a la proteína de la espícula de coronavirus sars-cov-2
CL2024002462A1 (es) Anticuerpos capaces de unirse a la proteína de la espícula de coronavirus sars-cov-2
MX2024010980A (es) Formas polimórficas de aticaprant para usar en el tratamiento del trastorno depresivo mayor
MX2021010834A (es) Compuesto y metodo para la prevencion de transmision del virus de influenza.
WO2021184128A8 (en) Methods of treating a coronavirus infection using colchicine
MX2022012001A (es) Tratamiento preventivo de la migra?a.
MX2022001450A (es) Metodo de tratamiento del cancer.
CO2025004675A2 (es) Método para tratar vih con cabotegravir y rilpivirina en pacientes pediátricos
MX2022011138A (es) Efecto contra coronavirus y aplicacion de inhibidor de fosfatidilinositol 4-cinasa.
NO20055512L (no) Terapi eller prevensjon av respiratoriske, virale infeksjoner med alfa-tyimosinpeptider
JOP20210347A1 (ar) طرق لعلاج فيروس نقص المناعة البشرية
JP1735110S (ja) 医療用電極
JP1735109S (ja) 医療用電極